CRISPR-based editing strategies to rectify EYA1 complex genomic rearrangement linked to haploinsufficiency

Participants

All procedures were approved by the Institutional Review Board of Seoul National University Hospital (IRB-H-0905-041-281 and IRB-H-2202-045-1298). In this study, one BOR/BO multiplex family segregated with CGR was included in the Hereditary Hearing Loss Clinic within the Otorhinolaryngology division of the Center for Rare Diseases, Seoul National University Hospital, Korea. The demographic data and clinical phenotypes were retrieved from electronic medical records. The presence and severity of associated medical conditions were determined using the Tenth Revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) codes and/or features in their clinical manifestations.

Whole-exome sequencing and Multiplex Ligation-dependent Probe Amplification

Genomic DNA was extracted from peripheral blood samples and used in whole- exome sequencing (WES) via SureSelectXT Human All Exon V5 (Agilent Technologies, Santa Clara, CA, USA). Adhering to the instructions provided, we prepared a library which was then sequenced using a NovaSeq 6000 system (Illumina, San Diego, CA, USA) in a paired-end manner. Sequence reads were compared to the human reference genome (GRCh38) and processed in line with the Genome Analysis Toolkit best-practice guidelines to identify single nucleotide variants (SNVs) and indels¹¹. The ANNOVAR program was used for variant annotation, such as from the RefSeq gene set and gnomAD^12,13. Rare non-silent variants were selected as candidates, including nonsynonymous SNVs, coding indels, and splicing variants. We also used the KRGDB and KOVA databases for further filtration of ethnic-specific variants^14,15. We conducted a comprehensive bioinformatics analysis to detect candidate variants using a defined filtering process, as described previously^16–18.

We also assessed the copy number status of EYA1 using a SALSA Multiplex Ligation-dependent Probe Amplification (MLPA) P461 DIS Probemix kit (MRC- Holland, Amsterdam, Netherlands). The amplification products were analyzed with an ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA), and the results were interpreted with the aid of Gene Marker 1.91 software (SoftGenetics, State College, PA, USA).

Whole-genome sequencing and bioinformatics

Genomic DNA was extracted from peripheral blood samples using Allprep DNA/RNA kits (Qiagen, Venlo, Netherlands) and libraries were generated with TruSeq DNA PCR-Free Library Prep Kits (Illumina). The libraries were then sequenced on the Illumina NovaSeq6000 platform with the coverage set at an average depth of 30×. The obtained sequences were aligned to the human reference genome (GRCh38) using the BWA-MEM algorithm and PCR duplicates were eliminated using SAMBLASTER. Mutation calling for base substitutions and short indels was achieved with HaplotypeCaller2 and Strelka2, respectively. Delly was used to identify SVs. The breakpoints of the genomic rearrangements of interest were visually examined and validated. Variant filtering and assessment of their Mendelian inheritance patterns were carried out. The pathogenicity of the variants was classified using the American College of Medical Genetics and Genomics/Association for Molecular Pathology guidelines¹⁹.

Cell culture and transfection

Patient fibroblasts were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin/amphotericin. To induce the correction of pathogenic inversion, 2×10⁵ patient fibroblasts were transfected with 17 μg Cas9 protein, 5 μg of in vitro transcribed gRNA targeting the A-B junction, and 5 μg of in vitro transcribed gRNA targeting the B-C junction using an Amaxa P3 Cell Line 4D- Nucleofector Kit (CM-137 program). Cells were analyzed 3 days after transfection.

HEK293T cells (American Type Culture Collection, ATCC, CRL-11268) were maintained in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. For dCas9-VP64 mediated EYA1 activation, HEK293T cells were seeded onto 24-well plates and transfected with 2,000 ng of plasmid DNA encoding dSaCas9-VP64 and gRNA (Addgene plasmid #158990) using 3 μL Lipofectamine 2000 (Life Technologies). After 72 h, total RNA was isolated with an RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions.

Targeted deep sequencing

Genomic DNA containing the on-target was amplified using KAPA HiFi HotStart DNA polymerase. The amplified products were designed to include Illumina TruSeq HT dual index adapter sequences. Subsequently, the amplified products were subjected to 150-bp paired-end sequencing using the Illumina iSeq 100 platform. To calculate the frequencies of insertions and deletions (indels), we used the MAUND tool, which is available at https://github.com/ibs-cge/maund.

Digital droplet PCR

Molecular analysis of the CGR derived from WGS was conducted using breakpoint PCR and digital droplet PCR (ddPCR). Genomic DNA extracted from patients was used to perform ddPCR with the QX200 ddPCR system (Bio-Rad). Procedures followed the manufacturer’s protocol with minor modifications. Briefly, the master mix for ddPCR consisted of 100 ng of genomic DNA, 1×ddPCR supermix for probes (no dUTP; 186-3023, Bio-Rad), 1.0CμM primer, and 0.25CμM probe (Metabion, Germany). Primers and a probe were designed for EYA1 breakpoint junctions (Supplementary Table 1). The samples were thoroughly combined before being put into a Bio-Rad QX100/QX200 droplet generator’s DG8 cartridge. The cartridge was then put into the QX200 Droplet Generator (Bio-Rad) and Droplet Generation Oil was added. After droplet formation, the droplets were carefully moved to a twin-tec semi-skirted 96-well PCR plate (EP0030128575, Eppendorf). PCR was then carried out in a C1000 Touch thermal cycler (Bio-Rad) for the two-step running program of 94°C for 30s and 56 °C for 1min for 40 cycles with an initial and final incubation at 95°C and 98 °C, respectively. The signal in each droplet was read by using a droplet reader and analyzed using the QuantaSoft program (Version 1.7, Bio-Rad).

RNA isolation and real-time quantitative PCR

Total RNA (1 μg) was extracted from either fibroblasts or HEK293T cells using the TRIzol method, with subsequent purification via Rneasy mini-columns (Qiagen) and an incorporated on-column Dnase I treatment. The synthesis of cDNA was achieved from 2 μg of the isolated total RNA using the reverse transcription (RT)-PCR method and Accupower RT-pre-mix (Bioneer). Quantitative RT-PCR assays were performed on cDNA samples diluted 1/20 using SYBR qPCR master mix (Kapa Biosystems, USA) as the reporter dye. Primers at a concentration of 10 pmol were used to detect specific gene mRNA expression. Their sequences were as follows: SOX2, forward 5′-GCTACAGCATGATGCAGGACCA-3′ and reverse 5′- TCTGCGAGCTGGTCATGGAGTT-3′; NEUROG1, forward 5′-GCCTCCGAAGACTTCACCTACC-3′ and reverse 5′- GGAAAGTAACAGTGTCTACAAAGG-3′; GFI1, forward 5′-GCTTCAAGAGGTCATCCACACTG3′ and reverse ACCTGGCACTTGTGAGGCTTCT-3′; and GAPDH, forward 5′- GAGTCAACGGATTTGGTCGT-3′ and reverse 5′- GACAAGCTTCCCGTTCTCAG-3′.

The primer sequences for EYA1 can be found in the Supplementary tables. The relative frequency of EYA1 mRNA was determined using the comparative C_T method²⁰.

Luciferase reporter gene assay

The luciferase reporter gene assay was performed, as described previously with slight modifications¹⁷. Briefly, HEK293T cells were transfected initially with three distinct plasmids: pGL4.12[luc2CP]-MYOG-6xMEF3, pRK5-SIX1, and pRL/CMV (E2261, Promega). Post-transfection, the cells were harvested for a luciferase assay using a Dual-Luciferase Reporter Assay kit (E1910, Promega), following the manufacturer’s guidelines. Transfection efficiency was adjusted based on Renilla activity, which was assessed after co-transfection with pRL/CMV.

Generating single cell-derived EYA1 knockout clones

HEK293T cells were maintained in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. For the transfection, the cells were seeded in 24-well plates and co-transfected with 1500 ng of the Cas9 expression plasmid and 500 ng of a sgRNA-encoding plasmid containing a spacer sequence (5′- ATGCCACGTACCCACAGCC-3′ on the top strand and 5′- GGCTGTGGGTACGTGGCAT-3′ on the bottom strand). Single-cell clones were generated via limiting dilutions in 96-well plates, followed by clonal expansion. Genomic DNA from these clones was isolated using Allprep DNA/RNA kits (Qiagen) according to the manufacturer’s instructions, and mutation frequencies were determined through targeted deep sequencing.

Immunoblotting

Cells were washed with PBS and lysed using RIPA buffer supplemented with protease inhibitors. The lysates combined with sample buffer were denatured at 85°C in preparation for SDS-PAGE. Subsequently, proteins were transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were blocked in 5% nonfat milk in TBS-T and then probed with primary antibodies. After comprehensive washing, membranes were exposed to horseradish peroxidase-linked secondary antibodies, specific to rabbit or mouse IgG. Protein bands became evident upon chemiluminescence application and were subsequently imaged. Band intensities were quantified using ImageJ software based on replicated experiments. Statistical evaluation was conducted using GraphPad Prism V5. Results with a p-value < 0.05 were used to confirm significance. Sources of antibodies and working dilutions were as follows: beta-actin, anti-β-actin (A1978, Sigma, 1/10,000); anti-EYA1 (22658-1-AP, Proteintech, 1/1,000).

Identification of a novel complex genomic rearrangement in the EYA1 gene

The proband, mother of the proband and affected siblings in SNUH family exhibited a range of clinical phenotypes associated with BOR/BO syndrome, demonstrating complete penetrance but variable expressivity of clinical phenotypes (Figure 1a). A bioinformatics approach and filtering strategy of WES results, aimed at prioritizing candidate causal variants for BOR/BO syndrome, yielded negative results. The sequential MLPA test showed a normal copy number state in EYA1 (Supplementary Figure 1). A thorough examination of a region on chromosome 8 was conducted by leveraging SV profiles via family-based WGS. This process revealed a novel CGR involving an EYA1 inversion (g.71211857 to g.71228236; with a 5′-breakpoint in intron 16 of EYA1 and a 3′-breakpoint in intron 12 of EYA1), with a deletion at the end of the segment (g.71211857 to g.71215145; with both the 5′-breakpoint and 3’- breakpoint located in intron 16) (Figure 1b and Supplementary Figure 2). We identified two neo-junctional reads, one with 1 bp of microhomology (A-B, g.71215145) and the other with 2 bp of microhomology (B-C, g.71228236) (Supplementary Figure 3). To confirm the breakpoint junctions identified by WGS, we designed four pairs of forward and reverse primers (Supplementary Table 1). Gap-PCR revealed the amplification of a 954-bp PCR product corresponding to the breakpoint within intron 16 (A-B junction) and a 235-bp PCR product corresponding to the breakpoint within intron 12 (B-C junction) (Figure 1c). We also verified the genomic sequence of junctions by Sanger sequencing (Figure 1c). The CGR in EYA1 results in a frameshift variant, leading to a premature stop codon at codon CTA within exon 16. This stop codon results in a truncated non-functional protein that lacks 210 amino acids at the C-terminal end, a region that includes the functional EYA domain (Figure 1d).

• Download figure
• Open in new tab

Figure 1. Pedigrees, clinical phenotypes, and two novel EYA1 SVs harboring BOR/BO syndrome

(a) Pedigree of the SNUH family with BOR/BO syndrome. The symbols in the pedigree indicate the following: circle, female; square, male. (b) Schematic representation illustrating the orientation and location of genomic segments reconstructed with the complex genomic rearrangement (CGR). The genomic coordinates of the breakpoints (depicted by red, blue, and green dotted vertical lines) demarcate the junctions of the segments. The colors of the bars on the breakpoint junction correspond to the following genomic positions: red, 71197433-71211857; blue, 71211857-71228236; orange, 71228236-71548094. The coding sequence configuration is depicted as connected segments. (c) Gap-PCR results align with the breakpoints identified through WGS. Sanger sequencing verified the generated PCR products. (d) The predicted effect of the EYA1 CGR on protein and domain structure. The solid red arrow represents the position of the inverted exon 16 (e16), whereas the dotted arrow denotes the position of the inverted exon 13 (e13). The abbreviations used in the domain map are defined as follows: e, exon; ED, EYA domain

Cas9 nuclease with paired gRNAs induce efficient editing at sites of the paracentric inversion

To assess the potential of Cas9 nucleases with paired gRNA for correcting the pathogenic inversion in patient-derived fibroblasts (Figures 2a and 2b), we designed gRNAs that specifically target the junction sites between fragment A and the inverted B (13 kb) fragment, as well as between the inverted B (13 kb) and C fragments (Figure 2c). We transfected patient fibroblast cells with complexes of Cas9 protein and in vitro transcribed gRNAs targeting the fragment junctions (Figure 2c), and measured editing frequencies using targeted deep sequencing (Figure 2d). The editing efficiency at target sites AB-T1 and AB-T2, located at the junction between fragment A and the inverted B (13 kb) fragment (A-B junction), were found to be 36.9% and 1.9%, respectively. Similarly, the Cas9 nuclease targeting the junctions between the inverted B (13 kb) fragment and fragment C (B-C junction) at sites BC-T1, BC-T2, and BC-T3 showed editing efficiencies of 57.2%, 89.0%, and 78.6%, respectively. Based on these results, we selected Cas9 nucleases targeting either AB-T1 and BC- T2 or AB-T1 and BC-T3 to induce the correction of the pathogenic inversion.

• Download figure
• Open in new tab

Figure 2. Dual Cas9 nuclease mediated correction of EYA1 pathogenic complex

(a) Schematic representation of Cas9 nuclease and paired gRNA-mediated correction of the pathogenic inversion. The dashed lines represent the Cas9 target sites. (b) Schematic representation of the mature mRNA anticipated after correction of the pathogenic inversion. (c) The Cas9 target sequences at the A-B junction and B-C junction of the pathogenic EYA1 gene in patient fibroblasts. The protospacer adjacent motif is highlighted in red. (d) Mutation frequencies induced by Cas9 nuclease at the A-B junction and B-C junction of the EYA1 gene. (e) Detection of Cas9 nuclease-mediated inversions using inversion-specific primers. (f) Targeted deep sequencing reads of amplicons generated using inversion-specific primers. (g) Estimation of inversion frequencies by digital PCR analysis using serially diluted samples. Diluted genomic DNA samples were subjected to PCR using inversion- specific primers. The results were analyzed using the Extreme Limiting Dilution Analysis program (http://bioinf.wehi.edu.au/software/elda/).

We next investigated whether Cas9 nuclease with paired gRNAs could correct the pathogenic inversion between endogenous loci in patient-derived fibroblasts (Figure 2a). To induce a paracentric inversion between the A-B junction and B-C junction, we co-transfected Cas9 protein and paired gRNAs targeting the two junctions. We then amplified the expected inversion junctions with paracentric inversion-specific primer pairs and found that inversions were induced in cells transfected with Cas9 protein and paired gRNAs (Figure 2e). To further analyze these amplicons, we performed targeted deep sequencing and found that Cas9 nuclease could induce a paracentric inversion that corrects the pathogenic inversion with additional small insertions or deletions (indels) at the junctions in patient-derived fibroblast cells (Figure 2f). To measure the inversion frequencies induced by Cas9 nuclease and paired gRNAs, we used dilution PCR^21,22. Through this analysis, we observed that the inversion frequency induced by Cas9 nuclease and paired gRNAs was up to 1.6% in patient-derived fibroblast cells (Figure 2g). These results demonstrate that Cas9 nuclease and paired gRNAs, which are specific to the patient’s genome, can correct the pathogenic inversions with relatively high efficiency in patient-derived fibroblasts.

Cas9 nuclease with paired gRNAs restores EYA1 expression and transcriptional activity

We assessed whether the Cas9 nuclease with paired gRNAs could restore the variant allele frequency (VAF) of the inversion junctions in patient cells using ddPCR (Figure 3a). We designed a primer/probe set that targeted both reference and mutated gene sequences at the A-B and B-C breakpoint junctions (Figure 3b). The VAF of the A-B and B-C junctions compared to the reference gene in patient fibroblast cells were 0.507 and 0.488, respectively. Notably, in the edited cells in which the AB-T1 and BC-T2 sites were targeted, the VAF of the A-B and B-C junctions decreased to 0.381 and 0.181, respectively. Similarly, the ratios dropped to 0.392 and 0.233 when AB-T1 and BC-T3 were targeted (Figure 3c). To verify that the genome editing elicited a recovery of the EYA1 transcript, we conducted quantitative reverse transcription PCR (qRT-PCR) with a primer set that covered the breakpoint junctions (Supplementary Table 3). Targeting both combinations of sites (AB-T1 with BC-T2 and AB-T1 with BC-T3) led to a significant increase in the amount of wild-type EYA1 transcripts (fig. 3d). To assess the potential restoration of the EYA1 transcriptional activity, we used a luciferase assay (Figure 3e). EYA1 encodes a transcriptional coactivator; the Eya domain is crucial for the formation of the EYA1-SIX1-DNA complex that regulates the transcription of target genes involved in the development of the branchial arch, otic system, and renal system²³. In this context, we used the pGL4.12[luc2CP]-MYOG-6xMEF3 construct, which incorporates a luciferase reporter along with six repeats of the MEF3 motif. Importantly, each motif exhibits a specific affinity for the EYA1 and SIX1 protein complex. Under the conditions of SIX1 overexpression, we observed that the luciferase activity in the EYA1 mutant significantly decreased to 12.7% of the wild- type levels, representing a 7.8-fold reduction. On the other hand, cells with edited genes displayed a substantial increase in luciferase activity relative to the mutant, with increases of 2.7-fold at the AB-T1 and BC-T2 sites, and 3.4-fold at the AB-T1 and BC-T3 sites. These levels correspond to 34.1% and 43.8%, respectively, of those observed in control cells. Although it is essential to investigate the downstream target gene expression and the modifications in the transcriptome tied to EYA1 transcriptional activity, our data suggest that the dual Cas9 nucleases, designed to specifically target the paracentric inversion in the patient genome, are capable of restoring the transcriptional functionality of EYA1.

• Download figure
• Open in new tab

Figure 3.

Restoration of EYA1 gene expression(a) Schematic workflow of digital droplet PCR (ddPCR). The genomic DNA was subjected to amplification after partitioning into each droplet, see (a) and (b). Multiple fluorescent signals were detected to fit into the Poisson distribution, see (c), to calculate absolute concentration. (b) Primer and probe design. EYA1 wild-type and complex SV-specific forward and reverse primers were used to verify the breakpoint junction. (c) Two-dimensional plots of ddPCR results represent the EYA1 variant allele frequency at each breakpoint junction. The colored dots in the 2D plot indicate the following: gray, negative droplets; blue, droplets with mutant allele; green, droplets with wild-type allele; orange, droplets with both mutant and wild-type alleles. Genomic DNA was isolated from the EYA1 wild-type (control), EYA1 mutated (patient), and EYA1-edited fibroblast cells. p < 0.01*** (n = 3, one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test). (d) Wild-type EYA1 transcript levels in both patient-derived and edited fibroblast cells. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis was performed, and the GAPDH mRNA levels were used to normalize the levels of EYA1 expression. Each bar represents the means of percent values (relative to the EYA1 mRNA levels in wild-type fibroblast cells) ± SEM from three independent experiments. (*, p < 0.05; **, p < 0.01 one-way ANOVA with Bonferroni post hoc test) (e) Fibroblast cells were concurrently transfected with an MYOG promoter-driven luciferase reporter and the SIX1 wild-type construct. Relative luciferase activity (wild-type as control) was plotted as mean ± SEM (n = 3), *, p < 0.05, **, p < 0.01***, p < 0.001 (one-way ANOVA followed by Bonferroni’s multiple comparison test). (f) Total RNA was isolated, and the target genes (SOX2, GFI1, NEUROG1, and ATOH1) of EYA1 were analyzed by qRT-PCR. GAPDH mRNA levels were used to normalize the results. Values are represented as the mean ± SEM of three independent experiments (N = 3); *, p < 0.05, **, p < 0.01, ***, p < 0.001 (n = 3, one-way ANOVA with Bonferroni’s multiple comparison test).

In the literature, EYA1 CGRs involving inversions and deletions have been well-documented in BOR/BO cases^24,25. Consistent with this, our in-house database revealed that two unrelated BOR/BO families were segregated with CGRs (Supplementary Figure 2), including a cryptic large inversion, accounting for 18% (Supplementary Table 4). Thus, the dual CRISPR/Cas9 system developed herein has the potential to correct pathogenic SVs, including those with EYA1 CGRs, implicated in human genetic disorders.

Development of EYA1 CRISPR activator for haploinsufficiency

The pathogenic inversion occurring in the EYA1 leads to nonsense-mediated mRNA decay, resulting in haploinsufficiency (Figures 1d and 3d). Notably, when the cells were treated with cycloheximide (CHX), stabilization of the EYA1 transcript was observed, suggesting that the haploinsufficiency of EYA1 is dependent on NMD (Figure 4a). To investigate the potential of CRISPRa for inducing increased endogenous EYA1 expression, we transfected plasmid DNA encoding dSaCas9- VP64 and gRNA targeting the EYA1 promoter into HEK293T cells and compared the relative expression of EYA1 mRNA in treated cells and control cells (Figure 4b). Using qRT-PCR, we observed that dSaCas9-VP64 led to a substantial 4.0-fold upregulation of EYA1 mRNA expression compared to untreated HEK293T cells. To model the potential haploinsufficiency originating from a variety of mechanisms and to evaluate the performance of the CRISPRa, we engineered HEK293T cells with either monoallelic or biallelic knockouts of EYA1 (Figure 4c). We then investigated whether co-expressing dSaCas9-VP64 with either gRNA2 or 3 affected the mRNA expression of EYA1 in these cell lines. Quantitative assessments of relative mRNA abundances indicated marked increases in wild-type and monoallelic knockout cells, with up to 3.7 and 1.4-fold increases, respectively, when compared to untreated cells. In contrast, cells with biallelic knockouts exhibited no discernible alterations in mRNA levels (Figure 4d). We further analyzed transcriptional activity of EYA1 through a luciferase-based reporter gene assay, aiming to assess the potential restoration of EYA1 functionality with CRISPRa (Figure 4e). Under normal conditions, the luciferase activity in both monoallelic and biallelic knockout cells showed substantial reductions, by 68.5% and 64.4%, respectively, compared to HEK293T cells. Conversely, cells subjected to CRISPRa had enhanced luminescence, with increases of 1.3-fold in HEK293 cells and 1.7-fold in monoallelic knockout cells relative to their untreated counterparts. Consistent with the results of mRNA levels, biallelic knockout cells were not affected by CRISPRa. In line with these observations, protein levels in CRISPRa-treated cells increased by 1.84-fold in HEK293T cells and 8.00-fold in monoallelic knockout cells (Figure 4f).

• Download figure
• Open in new tab

Figure 4. Designing a CRISPR activator strategy to elevate EYA1 levels

(a) Relative EYA1 transcript levels were determined by qRT-PCR. Fibroblast cells were treated with DMSO or CHX (50 μg/mL) for 6h. All values were normalized to the untreated wild-type cells data and plotted as mean ± SEM (n = 3), ***, p < 0.001 (one-way ANOVA followed by Bonferroni’s multiple comparison test). (b) (left) HEK293T Cells were transfected with CRISPRa. Subsequently, qRT-PCR was used to assess the expression of EYA1, and normalized to the expressions of the GAPDH housekeeping gene. Data are presented as the mean ± SEM (n = 3). (right) Graphical depiction of EYA1 gene’s promoter region including transcription start sites (TSS). gRNA1–gRNA4 represent target sites of CRISPRa. (c) Schematic representation of monoallelic and biallelic EYA1 KO cells with their genotypes. EYA1 haploinsufficiency was rescued using CRISPRa. (d) As in (b), except that dSaCas9- VP64 and either gRNA 2 or 3 were expressed in monoallelic and biallelic EYA1 knockout HEK293T cells, as well as wild-type HEK293T cells. Values represent relative mRNA levels compared to HEK293 cells without transfection (control). (e) The MYOG promoter-driven luciferase reporter and the SIX1 wild-type construct were introduced into HEK293T cells and variants with either monoallelic or biallelic EYA1 knockouts. Relative luciferase activity (relative to the HEK293T control) is plotted as mean ± SEM (n = 3), *, p < 0.05, **, p < 0.01 (one-way ANOVA followed by Bonferroni’s multiple comparison test). (f) As in (d), except that whole cell extracts were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) followed by immunoblotting (Upper). For quantification (Lower), signals from EYA1 were normalized to those of beta-actin. Bars represent the mean ± SEM. ***, p < 0.001 (n=3, two-tailed Student’s t-test).

In the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), we noted that 81 disease-causing EYA1 variants (pathogenic or likely pathogenic) were implicated in BOR/BO syndrome (Figure 5a and Supplementary Table 5). The majority (68%) of the documented EYA1 variants with BOR/BO phenotypes were loss-of-function, including nonsense, frameshift, canonical splicing, and SVs, resulting in haploinsufficiency (Figure 5b). Our results indicate that CRISPRa holds potential as a versatile genome editing approach to address EYA1 haploinsufficiency, including those involving CGRs, suggesting its significance for personalized genome-specific interventions.

• Download figure
• Open in new tab

Figure 5. Genomic landscape of disease-causing EYA1 variants implicated in BOR/BO syndrome

(a) Circos plot (https://github.com/SNUH-hEARgeneLab/WGS_analysis.) illustrating the distribution of all reported disease-causing EYA1 variants from the ClinVar database. On the outer domain, the EYA1 exons and corresponding reported variants are depicted, while the inner domain displays the EYA domain (ED) of EYA1. (b) Pie chart demonstrating the percentage of each variant type of EYA1 disease- causing variants associated with BOR/BO syndrome.